Understanding Lynch Syndrome: Genetic and Molecular Insights

by

Introduction

Lynch syndrome, or Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is a frequent hereditary cancer predisposition with a strong relationship with CRC and other malignancies. Although COLO-Lanschow colorectal cancer and Lynch syndrome are not occasional, they are seen with early age onset and are correlated with numerous other cancers, including endometrial, ovarian, and gastric. Lynch syndrome is a polyposis condition that originates from hereditary mutations of DNA mismatch repair genes that culminate in microsatellite instability. Understanding the genetic and molecular profile of Lynch syndrome to identify patients that may be susceptible to developing Lynch syndrome-related cancers is critical in screening, prevention, and management of the condition and hence is heavily researched in the oncology fraternity.

Genetic Features of Lynch Syndrome

Lynch syndrome is an inherited variant involving germline mutations of mismatch repair genes, with MLH1, MSH2, MSH6, and PMS2 being the most common. These genes are involved in the repair of errors that would have occurred during the process of DNA replication. When any of these genes are mutated, the MMR system is compromised, making way for the stewing of mutations all over the body. This buildup usually results in the growth of cancer, especially where new cells are quickly formed, as in the colon.

The mutations may also be inherited in an autosomal dominant fashion; this means that inheriting one altered gene from either parent can put a person at risk of Lynch syndrome. The penetrance of these mutations is also high; indeed, the lifetime risk of colorectal cancer may be up to 80% in individuals with definite germline mutations in MLH1 and MSH2. The risk for other kinds of cancer, including endometrial cancer, is raised dramatically as well.

Nucleotide Signatures: Microsatellite Instability

Microsatellite instability is a condition of genomic instability due to mutations in mismatch repair. Microsatellites are tandem repeats of the 1–6 bases, which are normally subject to slippage during replication. In normal cells, these kinds of mistakes get repaired because of the existence of a system known as the MMR system. If the cells are deficient for MMR, these errors are not corrected, and hence MSI is observed.

MSI can be found in about 15% of all colorectal cancers, although it is most closely associated with Lynch syndrome, which occurs in nearly all patients. Based on the degree of instability, MSI can be classified into three groups. MSI is also characterized by MSSI as high-frequency MSI, low-frequency MSI, and microsatellite stable. Given the less aggressive behavior and sensitivity to some chemotherapeutic agents, MSI-H tumors stand apart; MSI seems to turn into a useful factor for prognosis in CRC.

Yearwise Publication Trend on “lynch syndrome”

Find publication trends on relevant topics

Pathogenesis and Tumor Characteristics

Thus, the molecular action of Lynch syndrome-associated cancers is still manifestly other than the adenoma-carcinoma sequence that occurs in the majority of sporadic CRCs. In Lynch syndrome, colorectal cancer develops after the loss of function of one of the MMR genes and subsequent genetic instability in other important genes concerning cell proliferation and programmed cell death. The HNPCC cancers mainly develop in the proximal colon, whereas the sporadic CRCs are seen in the distal colon. Lynch syndrome tumors are seen to be of poor differentiation, mucinous type, and high TILs, which is a measure of immune reaction to tumors.

It is also conventional for Lynch syndrome tumors to exhibit mutations in the BAX gene or the TGFBRII gene. The BAX gene is implicated in apoptosis, and its aberration makes the cancer cells resistant to apoptosis and thus survive longer. TGFBRII belongs to the class of receptor type I that is implicated in the TGF-beta signaling that controls cell development and differentiation. There are indications that mRNA expression of TGFBRII is prognostic for better outcomes in LS patients, as such tumors are less malignant.

Diagnosis and Screening

Due to the high risk of cervical cancer among Lynch syndrome patients, it is crucial to diagnose the disease at an earlier stage and conduct regular screenings. Lynch syndrome is usually diagnosed with the help of criteria that include family history, clinical characteristics, and molecular testing. Lynch syndrome is established clinically by the Amsterdam Criteria and the revised Bethesda Guidelines to delineate people who require further testing. Molecular testing itself includes the evaluation of MSI and IHC of tumor tissue for MMR protein levels. Lack of expression of any of these proteins indicates that there is a defective gene of MMR associated. If MSI or loss of MMR protein expression is positive, then germline genetic testing is done along with the diagnosis of Lynch syndrome.

If there is a confirmed mutation in a family, then this can be followed up by predictive genetic testing of the other at-risk family members. It makes it possible to define those patients who might require additional monitoring and preventive measures, including, for instance, a colonoscopy at an earlier age than recommended for other individuals.

Recent Publications on “lynch syndrome”

Find publications on relevant topics

Management and Prevention

Monitoring of Lynch syndrome involves screening for the development of colorectal and other related malignancies and has specific indications for surgical prophylaxis. Colonoscopy thus forms the mainstay of cancer prevention in Lynch syndrome because histologically adenomatous polyps can be identified endoscopically and surgically removed at a curable stage. The frequency for this examination is not fixed, but colonoscopy should be done every 1 to 2 years, starting from the age of 20 to 25, or 2 to 5 years before the youngest age of colorectal cancer in the family.

Women with Lynch syndrome should also be recommended to undergo screening tests for very frequent endometrial and ovarian cancers. In cases where a strong family history is noted for these cancers, a prophylactic hysterectomy and oophorectomy may be considered following fecundity. Another area of research in Lynch syndrome is that of chemoprevention. Results of some studies indicate that aspirin intake reduces the incidence of CRC in LS patients, but the dosage and duration of aspirin therapy are highly speculative. The NSAIDs have also been given, although the effectiveness and the possible side effects on cancer patients have not spurred further research.

Genetic Counseling and Family Planning

Since Lynch syndrome is genetic, genetic counseling as part of its management is mandatory. A genetic counselor is a healthcare professional who can advise individuals and families on the results of genetic tests, the likelihood of getting cancer, and the choice of a mate.

To reduce the risk of transmission of Lynch Syndrome genes to the next generation, those with the complication and who are willing to conceive may consider PGD and prenatal diagnostic techniques. As for these options, they bring about multiple ethical and emotional questions that should be discussed with the help of a genetic counselor.

Directions for Lynch Syndrome Research

Current research in Lynch syndrome is still ongoing due to the discovery of new research developments in the genetic and molecular foundations of the syndrome, besides research on new and efficient ways of diagnosing, preventing, and treating the syndrome. Due to the technological expansion of next-generation sequencing and other genomic technologies, new genetic mutations that contribute to Lynch syndrome and other related cancer syndromes may be discovered. These findings could help to develop unified mutation panels and individual strategies regarding the risk of cancer development.

Another important field of investigation is immunotherapy, which, for example, has shown outstanding results in MSI-H tumors. Lynch Syndrome has revealed these therapies to be effective in the treatment of advanced cancers and a new shot of hope for individuals with limited probabilities of treatment.

Conclusion

Lynch syndrome is a complex and, in many aspects, an intricate medical condition that has many implications for the patient and their family as well as for health care practitioners. However, with the success of the genetic and molecular investigation, there are prospects for increased diagnosis, control, and, in the long run, prevention of the cancers related to this syndrome. These results can help the evaluation, diagnosis, and treatment of patients with Lynch syndrome and make progress in the anti-cancer campaign of hereditary cancer.

References

  1. Umar, A., 2004. Lynch syndrome (HNPCC) and microsatellite instability. Disease markers, 20(4-5), pp.179-180.
  2. Lynch, H.T. and Lynch, J.F., 2004. Lynch syndrome: history and current status. Disease markers, 20(4-5), p.181.
  3. Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M., Hamilton, S.R., Laurent-Puig, P., Gryfe, R., Shepherd, L.E. and Tu, D., 2003. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New England Journal of Medicine, 349(3), pp.247-257.
  4. Greenson, J.K., Bonner, J.D., Ben-Yzhak, O., Cohen, H.I., Miselevich, I., Resnick, M.B., Trougouboff, P., Tomsho, L.D., Kim, E., Low, M. and Almog, R., 2003. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. The American journal of surgical pathology, 27(5), pp.563-570.
  5. Samowitz, W.S., Curtin, K., Neuhausen, S., Schaffer, D. and Slattery, M.L., 2002. Prognostic implications of BAX and TGFBRII mutations in colon cancers with microsatellite instability. Genes, Chromosomes and Cancer, 35(4), pp.368-371.
  6. Suraweera, N., Duval, A., Reperant, M., Vaury, C., Furlan, D., Leroy, K., Seruca, R., Iacopetta, B. and Hamelin, R., 2002. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology, 123(6), pp.1804-1811.
  7. Raedle, J., Schaffner, M., Esser, N., Sahm, S., Trojan, J., Kriener, S., Brieger, A., Nier, H., Bockhorn, H., Berg, P.L. and Frick, B., 2002. Frequency of the Amsterdam criteria in a regional German cohort of patients with colorectal cancer. Zeitschrift für Gastroenterologie, 40(08), pp.561-568.

Top Experts on “lynch syndrome“